Analyst Ratings For Acasti Pharma Inc (NASDAQ:ACST)
Today, B. Riley initiated coverage on Acasti Pharma Inc (NASDAQ:ACST) with a Buy with a price target of $7.75.
There are 5 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Acasti Pharma Inc (NASDAQ:ACST) is Buy with a consensus target price of $6.9375 per share, a potential 305.70% upside.
Some recent analyst ratings include
- 8/29/2019-Acasti Pharma Inc (NASDAQ:ACST) has coverage initiated with a Buy rating and $7.75 price target
- 8/15/2019-Acasti Pharma Inc (NASDAQ:ACST) had its Buy rating reiterated by HC Wainwright
- 7/18/2019-Acasti Pharma Inc (NASDAQ:ACST) has coverage initiated with a Outperform ➝ Outperform rating and $7.00 price target
- 7/18/2019-Acasti Pharma Inc (NASDAQ:ACST) has coverage initiated with a Outperform rating and $7.00 price target
- 7/9/2019-Acasti Pharma Inc (NASDAQ:ACST) has coverage initiated with a Buy rating
- 1/29/2018-Acasti Pharma Inc (NASDAQ:ACST) had its Buy rating reiterated by Dawson James
- 1/5/2018-Acasti Pharma Inc (NASDAQ:ACST) has coverage initiated with a Buy rating and $7.00 price target
Recent Trading Activity for Acasti Pharma Inc (NASDAQ:ACST)
Shares of Acasti Pharma Inc closed the previous trading session at 1.71 up +0.030 1.79% with 1.74 shares trading hands.
